期刊
CANCER LETTERS
卷 332, 期 2, 页码 229-236出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.07.030
关键词
Tumor suppressor genes; p73; p53; Molecular therapy
类别
资金
- European Research Council (P73CANCER)
- Deutsche Forschungsgemeinschaft [KFO210 STI182/3-1, TR81, A10]
- Deutsche Krebshilfe [107904]
- Deutsche Jose Carreras Leukamie-Stiftung [R 09/09]
- von Behring-Rontgen-Stiftung [51-0077]
- Kind-Philipp-Stiftung fur Leukamieforschung
- LOEWE (UGMLC, Tumor Inflammation)
p73 is a member of the p53 family of tumor suppressors. Transactivating isoforms of p73 (TAp73) have p53-like, anti-proliferative and pro-apoptotic activities that are crucial for an efficient chemotherapy response. In line with this, genetic studies in mice have confirmed that TAp73 acts as a tumor suppressor. However, in contrast to p53, which is commonly inactivated in human cancer by point mutations, the TP73 gene is almost never mutated. Instead, the tumor suppressor activity of TAp73 is inhibited through a variety of mechanisms including epigenetic silencing and complex formation with inhibitory proteins. All these mechanisms have in common that they are in principle reversible and therefore amenable to therapeutic intervention. Here, we will review how tumor cells control the tumor suppressor activity of TAp73 and discuss possible strategies targeting p73 for reactivation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据